Yes-associated protein (YAP) is a main mediator of the Hippo pathway and promotes cancer development and progression in human lung cancer. We sought to determine whether inhibition of YAP suppresses metastasis of human lung adenocarcinoma in a murine model. We found that metastatic NSCLC cell lines H2030-BrM3(K-ras G12C mutation) and PC9-BrM3 (EGFR Dexon19 mutation) had a significantly 
better response rate and fewer side effects than conventional chemotherapy in treating patients with EGFR mutant metastatic lung adenocarcinoma. [7] [8] [9] [10] K-ras mutation is frequent in patients with lung adenocarcinoma (15%-30%), but there is still no approved effective target therapy for K-ras mutant metastatic lung adenocarcinoma. [10] [11] [12] Yes-associated protein (YAP), a key mediator protein in the Hippo (also known as the Salvador-Warts-Hippo) signalling pathway, has been reported to promote development of various cancers. [13] [14] [15] YAP has been suggested as a potential therapeutic target for melanoma, mesothelioma and hepatocellular carcinoma. [16] [17] [18] YAP was also identified in human non-small-cell lung cancer (NSCLC) and is correlated with drug resistance and tumorigenesis. 14, [19] [20] [21] A previous study reported that because some NSCLC cell lines harbouring K-ras mutations were not K-ras-dependent cells, K-ras may be not an appropriate therapeutic target. 22 Furthermore, YAP appears to take over K-ras as a cancer driver in NSCLC and pancreatic ductal adenocarcinoma, and YAP was identified as a central driver of compensation for K-ras-dependent NSCLC when there is loss of K-ras signalling. [23] [24] [25] Metastatic lung adenocarcinoma cell line H2030-BrM3 (K-ras G12C mutation) was derived from lung adenocarcinoma cell line H2030 (K-ras G12C mutation), which has a known cancer-driven K-ras mutation and a high potential of metastasis in murine models. 26, 27 Although an important regulator, serpin I1 (neuroserpin), was identified in H2030-BrM3 cells to promote brain metastasis, rare study found effective treatments for metastatic K-ras mutant lung adenocarcinoma in murine models. 27 We sought to determine whether there is increased Hippo/YAP signalling pathway reporter activity and YAP expression in metastatic lung adenocarcinoma cells. In addition, we investigated whether direct inhibition of YAP suppresses human lung adenocarcinoma H2030-BrM3 cell metastasis in vivo.
| MATERIALS AND METHODS

| Cell culture
Human metastatic NSCLC cell lines H2030-BrM3 (K-ras G12C mutation) (P9) and PC9-BrM3 (EGFR Dexon19 mutation) (P40) were kindly provided by Professor Joan Massagu e (Metastasis Research Center, Memorial Sloan Kettering Cancer Center, New York, NY) and authenticated by left ventricle inoculation as previously described. 26, 27 Parental human NSCLC cell line PC9 (P10) was a gift from Dr. Jasmine G. Lee (Department of Internal Medicine, Division of Respiratory Medicine, University of California Davis, Davis) and authenticated by erlotinib treatment in a viability assay. 28 Human NSCLC cell line H2030 was obtained from American Type Culture
Collections (ATCC) (Manassas, VA) and passaged for fewer than 6 months after receipt from ATCC. Cell lines were maintained in RPMI-1640 supplemented with 10% heat-inactivated foetal bovine serum and streptomycin (100 mg/mL), and were cultured at 37°C in a humid incubator with 5% CO 2 . 
| Animal studies
| Western blot analysis
The total amount of protein for each sample was 20 lg, and the samples were run on 4%-20% gradient SDS-polyacrylamide gels 
| Luciferase reporter assay
The control shRNA-transfected H2030-BrM3 and YAP shRNA- 
| Wound-healing and transwell invasion assays
| Statistical analysis
Data are expressed as mean AE standard deviation (SD) from three independent experiments. All statistical analyses were performed with GraphPad Prism (version 5.0; GraphPad Software, San Diego, CA, USA). t Tests were used to compare the differences between two groups, and one-way ANOVA followed by Tukey's multiple comparisons was used to compare differences among >2 groups. A Kaplan-Meier survival curve was calculated to determine survival in the animal experiments and patients in tissue microarray. All P values were 2-sided and considered to be statistically significant if P was less than .05 (*P < .05, **P < .01, ***P < .001).
3 | RESULTS survived significantly longer than mice inoculated with control shRNA-transfected H2030-BrM3 cells (P < .01) ( Figure 5C ). According to recent studies, YAP takes over K-ras as a cancer driver in NSCLC. [23] [24] [25] A previous study also identified that some NSCLC cell lines harbouring K-ras mutations were not K-ras-dependent cells, and that for those cell lines, K-ras may be not a therapeutic target. 22 Moreover, H2030 cells (K-ras G12C mutation) are not responsive to therapies targeting K-ras, mitogen-activated protein (MAP)-ERK kinase (MEK) and the extracellular signal-regulated kinase (ERK) signalling pathway. [29] [30] [31] [32] In our study, inhibition of K-ras by K-ras siRNA in H2030-BrM3 cells did not decrease YAP protein expression, which suggests these cells may not be K-ras-dependent.
Therefore, we investigated YAP as a therapeutic target for metastasis of H2030-BrM3 cells because they have increased YAP mRNA and YAP protein expression.
Another metastatic lung adenocarcinoma cell line PC9-BrM3
(EGFR Dexon19 mutation) was derived from PC9 cells (EGFR Dexon19 mutation) with a known EGFR exon 19 deletion mutation. 28, 31, 32 Currently, erlotinib is effective in treating metastatic lung adenocarcinoma harbouring EGFR exon 19 deletion mutation. 9, [33] [34] [35] [36] Our results showed that YAP protein expression decreased after erlotinib treatment and inhibition of EGFR by EGFR siRNA in PC9-BrM3 cells.
We recently reported crosstalk between Hippo/YAP and EGFR/extracellular signal-regulated kinase signalling pathways in human NSCLC cells. 19, 21 Collectively, PC9-BrM3 cells are dependent on the EGFR signalling pathway and inhibiting that pathway can inhibit the YAP signalling pathway and control metastasis of PC9-BrM3 cells.
Yes-associated protein transcription can be stimulated by SIRT1, 37 and SIRT1 is highly expressed in NSCLC brain metastasis tissues. 38 To our knowledge, our study is first to provide the key evidence that direct inhibition of YAP by shRNA suppresses lung 
